Efficient approach for determining four-dimensional computed tomography-based internal target volume in stereotactic radiotherapy of lung cancer

Seung-Gu Yeo, MD, PhD, Eun Seog Kim, MD, PhD
Department of Radiation Oncology, Soonchunhyang University College of Medicine, Cheonan, Korea

**Purpose:** This study aimed to investigate efficient approaches for determining internal target volume (ITV) from four-dimensional computed tomography (4D CT) images used in stereotactic body radiotherapy (SBRT) for patients with early-stage non-small cell lung cancer (NSCLC).

**Materials and Methods:** 4D CT images were analyzed for 15 patients who received SBRT for stage I NSCLC. Three different ITVs were determined as follows: combining clinical target volume (CTV) from all 10 respiratory phases (ITV_10Phases); combining CTV from four respiratory phases, including two extreme phases (0% and 50%) plus two intermediate phases (20% and 70%) (ITV_4Phases); and combining CTV from two extreme phases (ITV_2Phases). The matching index (MI) of ITV_4Phases and ITV_2Phases was defined as the ratio of ITV_4Phases and ITV_2Phases, respectively, to the ITV_10Phases. The tumor motion index (TMI) was defined as the ratio of ITV_10Phases to CTV_mean, which was the mean of 10 CTVs delineated on 10 respiratory phases.

**Results:** The ITVs were significantly different in the order of ITV_10Phases, ITV_4Phases, and ITV_2Phases (all p < 0.05). The MI of ITV_4Phases was significantly higher than that of ITV_2Phases (p < 0.001). The MI of ITV_4Phases was inversely related to TMI (r = –0.569, p = 0.034). In a subgroup with low TMI (n = 7), ITV_4Phases was not statistically different from ITV_10Phases (p = 0.192) and its MI was significantly higher than that of ITV_2Phases (p = 0.016).

**Conclusion:** The ITV_4Phases may be an efficient approach alternative to optimal ITV_10Phases in SBRT for early-stage NSCLC with less tumor motion.

**Keywords:** Four-dimensional computed tomography, Internal target volume, Lung cancer, Stereotactic body radiotherapy

---

**Introduction**

A considerable proportion of patients with early-stage non-small cell lung cancer (NSCLC) are unable or unwilling to undergo surgery, usually due to the presence of combined diseases or advanced age. The treatment of choice for such patients has usually been conventional radiotherapy (RT) using radiation doses of approximately 60 to 70 Gy delivered over 6 to 7 weeks. However, treatment outcomes were unsatisfactory with local failure rates as high as 60% to 70% in some series [1].

Over the past decade, stereotactic body RT (SBRT) has gradually replaced conventional RT for medically inoperable patients with early-stage NSCLC [2]. SBRT is a high-precision RT technique that delivers a highly conformal and hypofractionated ablative radiation dose over a short period of time. Up to 60 Gy is delivered in SBRT in as few as three
fractions within 1 week, with steep increases in the tumoricidal effect; 60 Gy in three fractions is presumed to be equal to as much as 150 Gy in conventional fractionation [2]. Several prospective trials of SBRT demonstrated impressive local control, exceeding 90% at 3 years, with acceptable toxicity for patients with inoperable early-stage NSCLC [3-5].

In lung SBRT, the technical aspects of RT including image guidance and motion management are of particular relevance. They critically depend upon precise target localization to deliver a high radiation dose per fraction, while the tumors move continuously due to respiration [6]. Four-dimensional computed tomography (4D CT) correlates respiratory motion with the CT acquisition process, providing patient-specific information about tumor size, shape, and position in different phases of the respiratory cycle. Patients breathe freely during CT acquisition, and the images are retrospectively sorted into 10 respiration-based bins [7].

To account for tumor motion, the International Commission on Radiation Units and Measurements Report 62 introduced the concept of an internal target volume (ITV), defined as the clinical target volume (CTV), plus an additional margin to account for geometric uncertainties due to variable tumor motion [8]. In 4D CT, an ideal method of determining ITV is accomplished by contouring the CTV on each of the 10 respiratory phase image sets. However, this poses some challenges due to the 10-fold increased workload for radiation oncologists. The aim of this study was to evaluate the suitability of ITV determination based on either two phases (peak-inspiration and peak-expiration) or four phases (peak-inspiration, peak-expiration, and two intermediate phases) using the ideal 10-phase-based ITV as a reference.

Materials and Methods

1. Patients
Fifteen patients with stage I NSCLC who underwent 4D CT simulation for treatment planning and received curative SBRT from 2011 to 2012 were analyzed retrospectively. Inclusion criteria for SBRT were as follows: pathologically confirmed NSCLC; clinical stage T1-2N0M0 according to the American Joint Committee on Cancer staging manual, 7th edition; longest tumor diameter of <5 cm; and Eastern Cooperative Oncology Group performance scale score of ≤2. The median age was 77 years (range, 68 to 86 years), and 10 patients (71.4%) were male. Only patients who were considered to be inoperable due to poor medical condition or refusal to undergo surgery were offered SBRT. The treated tumor was required to be further than 2 cm in all directions from the proximal bronchial tree [3].

2. ITV determination
During the 4D CT simulation, patients were immobilized in the supine position with the arms above the head in a vacuum-bag restriction system (Vac-Lock; CIVCO Medical Solutions, Kalona, IA, USA). Respiration-correlated 4D CT scans were performed during uncoached, quiet respiration using a Real-time Position Management system (Varian Medical Systems, Palo Alto, CA, USA) and a 16-slice CT scanner (Brilliance CT Big Bore; Philips Medical Systems, Cleveland, OH, USA) with a 0.2-cm slice thickness. Intravenous contrast was used in all patients. Data were acquired for the duration of a full respiratory cycle. Each reconstructed image was assigned to a specific respiratory phase to collectively yield a set of 10 CT images, each of which reflected 10% of the respiratory cycle. The gross tumor volume was delineated on the CT image for each respiratory phase using the ‘lung window’ setting. No expansion was made to account for microscopic disease extent, and the CTV was equivalent to the gross tumor volume.

Three approaches were utilized to determine the ITVs: 1) contouring the CTV on each of the 10 respiratory phases of the 4D CT data set and combining these CTVs to produce $\text{ITV}_{10\text{phases}}$; 2) combining 4 CTVs on the 0% (peak-inspiration), 20% (mid-expiration), 60% (peak-expiration), and 70% (mid-inspiration) respiratory phases to produce $\text{ITV}_{4\text{phases}}$; and 3) combining only 2 CTVs on both extreme respiratory phases (0% and 50%) to produce $\text{ITV}_{2\text{phases}}$. The planning target volume (PTV) was created by adding a 0.5-cm isotropic set-up margin around the ITV.

3. Analysis
The $\text{ITV}_{4\text{phases}}$ and $\text{ITV}_{2\text{phases}}$ were evaluated against $\text{ITV}_{10\text{phases}}$ by comparing the matching index (MI). Because $\text{ITV}_{4\text{phases}}$ and $\text{ITV}_{2\text{phases}}$ are completely enveloped by $\text{ITV}_{10\text{phases}}$, the MI value of $\text{ITV}_{4\text{phases}}$ and $\text{ITV}_{2\text{phases}}$ was defined as the ratio of $\text{ITV}_{4\text{phases}}$ and $\text{ITV}_{2\text{phases}}$ respectively, to the $\text{ITV}_{10\text{phases}}$. The maximum value of the MI is 1 if the two volumes are identical. The extent of tumor movement was expressed as the tumor motion index (TMI), defined by the ratio of $\text{ITV}_{10\text{phases}}$ to $\text{CTV}_{\text{mean}}$. The $\text{CTV}_{\text{mean}}$ was calculated as the mean value of 10 CTVs each delineated on 10 respiratory phases. Intergroup comparisons were conducted using the paired or independent-sample t-test, depending on the nature of the data. The correlation between TMI and MI, $\text{CTV}_{\text{mean}}$, or pulmonary function parameters was
Table 1. The CTV, ITV, PTV, tumor motion index, and matching index of all patients (n = 15)

|                      | Mean ± SD     | Range         |
|----------------------|---------------|---------------|
| CTV<sub>mean</sub> (cm<sup>3</sup>) | 14.8 ±16.1   | 1.5–58.0      |
| ITV (cm<sup>3</sup>)          | 23.0 ± 16.1   | 2.6–80.7      |
| ITV<sub>10Phases</sub>   | 21.3 ± 22.4   | 2.3–74.3      |
| ITV<sub>4Phases</sub>   | 20.1 ± 21.8   | 1.9–72.1      |
| PTV (cm<sup>3</sup>)          | 53.0 ± 46.5   | 10.8–161.6    |
| PTV<sub>10Phases</sub> | 49.6 ± 43.1   | 10.1–147.9    |
| PTV<sub>4Phases</sub>   | 47.5 ± 42.3   | 9.4–143.4     |
| Tumor motion index      | 1.6 ± 0.3     | 1.2–2.3       |
| Matching index          | 0.92 ± 0.04   | 0.81–0.98     |
| ITV<sub>4Phases</sub>   | 0.84 ± 0.08   | 0.67–0.97     |
| PTV<sub>4Phases</sub>   | 0.94 ± 0.02   | 0.88–0.97     |
| PTV<sub>2Phases</sub>   | 0.89 ± 0.04   | 0.81–0.94     |

SD, standard deviation; CTV, clinical target volume; ITV, internal target volume; PTV, planning target volume.

Results

Table 1 shows the CTV, ITV, PTV, TMI, and MI values of all patients. The tumor was located in the upper, middle, and lower lobe in 7, 1, and 7 patients, respectively. The tumors located in the lower lobe showed higher TMI, but with no statistical significance (lower lobe 1.7 ± 0.3 vs. mid-upper lobe 1.6 ± 0.3; p = 0.502). Similarly, the tumors having smaller size (CTV<sub>mean</sub>) showed higher TMI, but with no statistical significance (r = −0.304, p = 0.271). The pulmonary function data before SBRT were available in 12 patients, and the percentage predicted value of forced expiratory volume at 1 second (FEV1) and forced vital capacity (FVC) ranged 32%–134% (median, 81%) and 52%–142% (median, 88%), respectively. Patients with higher FEV1 or FVC showed higher TMI, but with no statistical significance (FEV1: r = 0.482, p = 0.133; FVC: r = 0.319, p = 0.339).

The ITV<sub>10Phases</sub>, ITV<sub>4Phases</sub>, and ITV<sub>2Phases</sub> were 23.0 ± 16.1, 21.3 ± 22.4, and 20.1 ± 21.8 cm<sup>3</sup>, respectively. There were significant differences between each ITV: 1) ITV<sub>10Phases</sub> vs. ITV<sub>4Phases</sub>, p = 0.002; 2) ITV<sub>10Phases</sub> vs. ITV<sub>2Phases</sub>, p = 0.001; and 3) ITV<sub>4Phases</sub> vs. ITV<sub>2Phases</sub>, p < 0.001. The MI of ITV<sub>4Phases</sub> (0.92 ± 0.04) was significantly higher than that of ITV<sub>2Phases</sub> (0.84 ± 0.08, p < 0.001). Also, the MI of PTV<sub>4Phases</sub> (0.94 ± 0.02) was significantly higher than that of PTV<sub>2Phases</sub> (0.89 ± 0.04, p < 0.001).

The MI of ITV<sub>4Phases</sub> was significantly correlated with TMI (r = −0.650, p = 0.009) (Fig. 1). When patients were grouped according to a median value of TMI (1.58), the ITV<sub>4Phases</sub> (20.5 ± 22.7 cm<sup>3</sup>) differed significantly compared with ITV<sub>10Phases</sub> (22.3 ± 24.1 cm<sup>3</sup>) in a group of patients (n = 8) with high TMI (p = 0.013). In contrast, the ITV<sub>4Phases</sub> (22.2 ± 23.8 cm<sup>3</sup>) did not differ statistically compared with ITV<sub>10Phases</sub> (23.9 ± 25.9 cm<sup>3</sup>) in a group of patients (n = 7) with low TMI (p = 0.192). Regarding PTVs in this group with low TMI, the difference between PTV<sub>10Phases</sub> (54.9 ± 49.0 cm<sup>3</sup>) and PTV<sub>4Phases</sub> (51.5 ± 44.4 cm<sup>3</sup>) was further decreased statistically (p = 0.204). Regardless of TMI, the MIs of ITV<sub>4Phases</sub> and PTV<sub>4Phases</sub> were significantly higher than those of ITV<sub>2Phases</sub> and PTV<sub>2Phases</sub>, respectively.

Discussion and Conclusion

SBRT is a safe and effective alternative therapy for patients with medically inoperable early-stage NSCLC [3–5]. As additional evidence, we recently reported favorable clinical outcomes, including local tumor control and low toxicity [2]. However, many of the original experiences with lung SBRT used standard, population-based margins for consideration of internal target movements and did not specifically delineate tumor contours that encompassed the tumor trajectory over the entire breathing cycle [9]. Such population-based estimates may overestimate or underestimate the margin needed for
Seung-Gu Yeo and Eun Seog Kim

radiation oncology journal ROJ

a given patient because breathing characteristics are quite variable among patients [10]. Overestimation increases the volume of healthy tissues exposed to high radiation dose, while underestimation results in missed targets and thus a decrease in tumor control. It has been shown that factors, such as tumor size, location, and pulmonary function tests cannot reliably predict respiration-driven lung tumor motion for an individual patient [11,12]. Similarly, in the present study, tumor size and location were not related to the extent of lung tumor movement (TMI). There are three basic methods of using 4D CT to deliver SBRT: an ITV method that uses static fields encompassing tumor motion during normal breathing, a gating method that synchronizes tumor location and ‘beam on’ timing, and tracking methods that track the tumor with continuous therapy [13]. The ITV approach is the most straightforward and most commonly adopted technique of the three methods. It has the potential to determine patient-specific ITVs to ensure adequate tumor coverage while minimizing unnecessary radiation to healthy tissues [14].

The need to contour CTVs in 10 respiratory phases to define the ITV is a major drawback to the routine clinical use of 4D CT scans. To reduce the workload of contouring multiple target volumes in 4D CT, a post-processing tool is occasionally used, including maximum intensity projection (MIP) images. The MIP reflects the highest data value encountered along the viewing ray for each pixel of volumetric data, displaying the brightest object along each ray [15]. However, Ezhil et al. [10] showed that MIP-based ITV determination underestimates the 10-phase-based ITV to a greater degree than does the extreme 2-phase-based ITV. The authors presented potential sources of uncertainty/error in the MIP-based approach as follows: the MIP image may not fully display mobile structures if the adjacent structures have similar (or higher) densities, which is the case for lesions located near the mediastinum, diaphragm, liver, or chest wall, and the tumor spicula cannot be visualized on the MIP because of smearing of the tumor edge. For the extreme 2-phase-based approach, tumor deformation between the two phases of breathing and the curved motion pathway during each breathing cycle may introduce uncertainty. They cautioned against adopting a method of ITV determination using MIP or an extreme 2-phase-based approach, which can miss a significant amount of tumor volume [10]. The present study also showed that the ITV_{2Phases} significantly underestimated ITV_{10Phases} even in patients with low TMI.

In conclusion, compared with the optimal but highly time-consuming ITV_{10Phases}, ITV determination based on four respiratory phases, including two extreme and two intermediate respiratory phases, did not significantly underestimate the tumor volume of the selected patients with low TMI while it reduced the workload by more than half. If ITV determination by ITV_{2Phases} is beyond the scope of routine clinical use, the ITV_{4Phases} method rather than ITV_{2Phases} may be an efficient alternative approach in SBRT for patients with early-stage NSCLC.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.
Acknowledgments

This work was supported by the Soonchunhyang University Research Fund.

References

1. Dosoretz DE, Katin MJ, Blitzer PH, et al. Medically inoperable lung carcinoma: the role of radiation therapy. Semin Radiat Oncol 1996;6:98-104.
2. Kim MJ, Yeo SG, Kim ES, Min CK, An PS. Intensity-modulated stereotactic body radiotherapy for stage I non-small cell lung cancer. Oncol Lett 2013;5:840-4.
3. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6.
4. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27:3290-6.
5. Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 2010;68:72-7.
6. Daly ME, Perks JR, Chen AM. Patterns-of-care for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States. J Thorac Oncol 2013;8:202-7.
7. Keall P. 4-dimensional computed tomography imaging and treatment planning. Semin Radiat Oncol 2004;14:81-90.
8. International Commission on Radiation Units and Measurements. ICRU Report 62: prescribing, recording, and reporting photon beam therapy (supplement to ICRU Report 50). Bethesda: International Commission on Radiation Units and Measurements; 1999.
9. Underberg RW, Lagerwaard FJ, Cuijpers JP, Slotman BJ, van Sornsen de Koste JR, Senan S. Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys 2004;60:1283-90.
10. Ezhil M, Vedam S, Balter P, et al. Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography. Radiat Oncol 2009;4:4.
11. Stevens CW, Munden RF, Forster KM, et al. Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function. Int J Radiat Oncol Biol Phys 2001;51:62-8.
12. van Sornsen de Koste JR, Lagerwaard FJ, Nijssen-Visser MR, Graveland WJ, Senan S. Tumor location cannot predict the mobility of lung tumors: a 3D analysis of data generated from multiple CT scans. Int J Radiat Oncol Biol Phys 2003;56:348-54.
13. Song DY, Kavanagh BD, Benedict SH, Schefter T. Stereotactic body radiation therapy: rationale, techniques, applications, and optimization. Oncology (Williston Park) 2004;18:1419-30.
14. Bradley JD, Nofal AN, El Naqa IM, et al. Comparison of helical, maximum intensity projection (MIP), and averaged intensity (AI) 4D CT imaging for stereotactic body radiation therapy (SBRT) planning in lung cancer. Radiother Oncol 2006;81:264-8.
15. Underberg RW, Lagerwaard FJ, Slotman BJ, Cuijpers JP, Senan S. Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer. Int J Radiat Oncol Biol Phys 2005;63:253-60.
16. Jin JY, Aijouni M, Chen Q, Yin FF, Movsas B. A technique of using gated-CT images to determine internal target volume (ITV) for fractionated stereotactic lung radiotherapy. Radiother Oncol 2006;78:177-84.
17. Boldea V, Sharp GC, Jiang SB, Sarrut D. 4D-CT lung motion estimation with deformable registration: quantification of motion nonlinearity and hysteresis. Med Phys 2008;35:1008-18.
18. Wolthus JW, Sonke JJ, van Herk M, et al. Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients. Int J Radiat Oncol Biol Phys 2008;70:1229-38.
19. Hof H, Rhein B, Haering P, Kopp-Schneider A, Debus J, Herfarth K. 4D-CT-based target volume definition in stereotactic radiotherapy of lung tumours: comparison with a conventional technique using individual margins. Radiother Oncol 2009;93:419-23.
20. Heinzinger JH, Anderson JF, Papiez L, et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys 2008;70:1571-8.